Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Concizumab (anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Daclizumab (anti-IL2RA) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (anti-IL2RA) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA.
Datopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and
Datopotamab (anti-TROP2) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan, TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan and